APA (7th ed.) Citation

L, A., S, B., T, P., O, B., L, L., C, R., . . . P, F. (2009). Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: Results of a phase 2 study. Blood, 113(17), 3947. https://doi.org/10.1182/blood-2008-08-175778

Chicago Style (17th ed.) Citation

L, Adès, et al. "Efficacy and Safety of Lenalidomide in Intermediate-2 or High-risk Myelodysplastic Syndromes with 5q Deletion: Results of a Phase 2 Study." Blood 113, no. 17 (2009): 3947. https://doi.org/10.1182/blood-2008-08-175778.

MLA (9th ed.) Citation

L, Adès, et al. "Efficacy and Safety of Lenalidomide in Intermediate-2 or High-risk Myelodysplastic Syndromes with 5q Deletion: Results of a Phase 2 Study." Blood, vol. 113, no. 17, 2009, p. 3947, https://doi.org/10.1182/blood-2008-08-175778.